Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SUNCIST: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Intravenous Administration of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Next Previous
X
Search
Trial Profile

SUNCIST: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Intravenous Administration of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Calmangafodipir (Primary)
  • Indications Chemotherapy-induced damage; Liver failure
  • Focus Adverse reactions
  • Acronyms SUNCIST
  • Sponsors Egetis Therapeutics; PledPharma

    • Most Recent Events

    • 09 Feb 2018 Status changed from recruiting to completed.
    • 01 Dec 2017 According to a PledPharma AB media release, first set of patients have been enrolled in the study and the data form this trial will be used for an expansion of the phase III clinical program, aims to include Asian patients.
    • 01 Dec 2017 Status changed from planning to recruiting, according to a PledPharma AB media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top